關(guān)鍵詞： VistaGen 干細(xì)胞
2013年4月12日訊 /生物谷BIOON/ --位于舊金山的制藥公司VistaGen宣布公司已經(jīng)籌集了3600萬美元用于支持公司的干細(xì)胞研究。公司是通過將股份出售給Bergamo Acquisition公司的形式來獲得該筆資金,。
公司CEO Shawn K. Singh表示在過去的十五年中,，公司投入了超過5000萬美元來研究利用干細(xì)胞技術(shù)治療人類心臟病等疾病。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
South San Francisco-based VistaGen Therapeutics says it's raised $36 million, selling shares to Bergamo Acquisition for 50 cents apiece. The biotech says it will use the cash to "accelerate and expand its stem cell technology-based drug rescue programs." "Since our inception nearly 15 years ago, we have carefully deployed more than $53 million, including over $15 million from grant awards and collaboration revenue, to successfully develop innovative stem cell technology and bioassay systems capable of bringing clinically relevant human heart and liver biology to the front end of the drug development process," stated CEO Shawn K. Singh.
